MAZE on Nasdaq
Maze Therapeutics, Inc.
American biological products company, incorporated in Delaware.
Price unavailable
Last updated Oct 18, 2026.
Overview
-$131.1MNet income, fiscal 20252
Compare with REGENXBIO Inc., Adaptimmune (United Kingdom) or Aerie Pharmaceuticals, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
Where the money goes
Where each dollar of revenue went, fiscal 2024
- Research and development50¢$83.5M
- Other costs18¢$30.6M
- Income tax1¢$1.2M
- Profit31¢$52.2M
Out of $167.5M in revenue.2
Where each dollar of operating cash went, fiscal 2024
- Capital spending2¢$1.1M
- Kept or used elsewhere98¢$74.8M
Out of $76.0M of cash from operations.2
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| License revenue | $167.5M | |
| Research and development | $108.4M | $83.5M |
| General and administrative | $34.5M | $26.4M |
| Total operating expenses | $142.9M | $109.9M |
| (Loss) income from operations | -$142.9M | $57.6M |
| Interest and other income, net | $11.8M | $4.7M |
| Change in fair value of convertible promissory notes | $0 | -$8.8M |
| (Loss) income before income tax expense | -$131.1M | $53.4M |
| Income tax expense | $0 | -$1.2M |
| Net (loss) income | -$131.1M | $52.2M |
| Net (loss) income attributable to common stockholders, basic (see Note 14) | -$131.1M | $3.4M |
| Net (loss) income attributable to common stockholders, diluted (see Note 14) | -$131.1M | $3.4M |
| Basic | -$3.05 | $1.42 |
| Diluted | -$3.05 | $1.25 |
| Basic | 43.0M shares | 2.4M shares |
| Diluted | 43.0M shares | 2.7M shares |
| Net unrealized gain on marketable securities | $110.0K | |
| Comprehensive (loss) income | -$131.0M | $52.2M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2025-02-28 | 2024-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $189.2M | $196.8M | |
| Marketable securities, current | $152.7M | ||
| Prepaid expenses and other current assets | $7.8M | $4.9M | |
| Total current assets | $349.7M | $201.7M | |
| Property and equipment, net | $5.0M | $6.7M | |
| Restricted cash | $1.1M | $1.1M | |
| Marketable securities, non-current | $18.1M | ||
| Operating lease right-of-use asset | $20.1M | $23.2M | |
| Other assets | $3.0M | $7.9M | |
| Total assets | $397.1M | $240.5M | |
| Accounts payable | $1.8M | $1.9M | |
| Accrued expenses and other current liabilities | $16.0M | $14.1M | |
| Operating lease liabilities, current | $4.8M | $4.6M | |
| Total current liabilities | $22.6M | $20.7M | |
| Operating lease liabilities, net of current portion | $18.5M | $22.0M | |
| Other liabilities, non-current | $1.1M | $969.0K | |
| Total liabilities | $42.2M | $43.6M | |
| Redeemable convertible preferred stock, $0.001 par value; no shares authorized, issued and outstanding as of December 31, 2025; 298,205,027 shares authorized and 297,205,041 shares issued and outstanding as of December 31, 2024; aggregate liquidation preference of $502,390 as of December 31, 2024 | $0 | $508.1M | |
| Preferred stock, $0.001 par value; 10,000,000 and no shares authorized as of December 31, 2025 and 2024, respectively; no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | |
| Common stock, $0.001 par value; 500,000,000 and 410,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 49,335,551 and 2,446,864 shares issued and outstanding as of December 31, 2025 and 2024, respectively; 10,372 shares subject to repurchase as of December 31, 2025 and 2024 | $49.0K | $2.0K | |
| Additional paid-in-capital | $844.4M | $47.2M | |
| Accumulated other comprehensive income | $110.0K | ||
| Accumulated deficit | -$489.5M | -$358.4M | |
| Total stockholders' equity (deficit) | $355.0M | -$311.2M | |
| Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | $397.1M | $240.5M | |
| Preferred stock, par or stated value per share | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | ||
| Common stock, par or stated value per share | $0.00 | $0.00 | $0.00 |
| Common stock, shares authorized | 500.0M shares | 500.0M shares | 410.0M shares |
| Common stock, shares, issued | 49.3M shares | 2.4M shares | |
| Common stock, shares, outstanding | 49.3M shares | 2.4M shares | |
| Common stock, shares, subject to repurchase | 10.4K shares | 10.4K shares |
| Period ending | 2025-12-31 | 2025-02-28 | 2024-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $189.2M | $196.8M | |
| Marketable securities, current | $152.7M | ||
| Prepaid expenses and other current assets | $7.8M | $4.9M | |
| Total current assets | $349.7M | $201.7M | |
| Property and equipment, net | $5.0M | $6.7M | |
| Restricted cash | $1.1M | $1.1M | |
| Marketable securities, non-current | $18.1M | ||
| Operating lease right-of-use asset | $20.1M | $23.2M | |
| Other assets | $3.0M | $7.9M | |
| Total assets | $397.1M | $240.5M | |
| Accounts payable | $1.8M | $1.9M | |
| Accrued expenses and other current liabilities | $16.0M | $14.1M | |
| Operating lease liabilities, current | $4.8M | $4.6M | |
| Total current liabilities | $22.6M | $20.7M | |
| Operating lease liabilities, net of current portion | $18.5M | $22.0M | |
| Other liabilities, non-current | $1.1M | $969.0K | |
| Total liabilities | $42.2M | $43.6M | |
| Redeemable convertible preferred stock, $0.001 par value; no shares authorized, issued and outstanding as of December 31, 2025; 298,205,027 shares authorized and 297,205,041 shares issued and outstanding as of December 31, 2024; aggregate liquidation preference of $502,390 as of December 31, 2024 | $0 | $508.1M | |
| Preferred stock, $0.001 par value; 10,000,000 and no shares authorized as of December 31, 2025 and 2024, respectively; no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | |
| Common stock, $0.001 par value; 500,000,000 and 410,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 49,335,551 and 2,446,864 shares issued and outstanding as of December 31, 2025 and 2024, respectively; 10,372 shares subject to repurchase as of December 31, 2025 and 2024 | $49.0K | $2.0K | |
| Additional paid-in-capital | $844.4M | $47.2M | |
| Accumulated other comprehensive income | $110.0K | ||
| Accumulated deficit | -$489.5M | -$358.4M | |
| Total stockholders' equity (deficit) | $355.0M | -$311.2M | |
| Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | $397.1M | $240.5M | |
| Preferred stock, par or stated value per share | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | ||
| Common stock, par or stated value per share | $0.00 | $0.00 | $0.00 |
| Common stock, shares authorized | 500.0M shares | 500.0M shares | 410.0M shares |
| Common stock, shares, issued | 49.3M shares | 2.4M shares | |
| Common stock, shares, outstanding | 49.3M shares | 2.4M shares | |
| Common stock, shares, subject to repurchase | 10.4K shares | 10.4K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net (loss) income | -$131.1M | $52.2M |
| Depreciation expense | $2.4M | $3.3M |
| Stock-based compensation expense | $16.4M | $9.6M |
| Non-cash lease expense | $3.1M | $2.9M |
| Accretion of discounts on marketable securities, net | -$505.0K | |
| Change in fair value of convertible promissory notes | $8.8M | |
| Other items, net | $21.0K | $577.0K |
| Prepaid expenses and other current assets | -$2.9M | $93.0K |
| Other assets | $537.0K | -$2.3M |
| Accounts payable | -$27.0K | -$204.0K |
| Accrued expenses and other liabilities | $3.5M | $3.8M |
| Operating lease liabilities | -$3.3M | -$2.9M |
| Net cash (used in) provided by operating activities | -$111.9M | $76.0M |
| Purchases of marketable securities | -$187.7M | |
| Maturities of marketable securities | $17.5M | |
| Purchases of property and equipment | -$794.0K | -$1.1M |
| Net cash used in investing activities | -$171.0M | -$1.1M |
| Proceeds from initial public offering, net of offering costs paid | $127.8M | |
| Proceeds from private placement, net of offering costs paid | $141.3M | |
| Proceeds from exercise of stock option awards, net of repurchases | $5.6M | $733.0K |
| Proceeds from issuance of common stock under the 2025 Employee Stock Purchase Plan | $1.3M | |
| Payment of success fee derivative | -$500.0K | |
| Proceeds from exercise of pre-funded warrants | $1.0K | |
| Payment of deferred offering costs | -$3.2M | |
| Proceeds from issuance of Series D redeemable convertible preferred stock, net of issuance costs | $70.8M | |
| Proceeds from issuance of convertible promissory notes, net of issuance costs | $24.5M | |
| Net cash provided by financing activities | $275.3M | $92.8M |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -$7.6M | $167.7M |
| Purchases of property and equipment recorded in accounts payable and accrued expenses | $5.0K | $59.0K |
| Vesting of restricted stock and stock options subject to repurchase | $23.0K | |
| Offering costs recorded in accounts payable and accrued expenses | $11.0K | $1.1M |
| Settlement of convertible promissory notes by conversion to Series D-1 redeemable convertible preferred stock | $53.4M | |
| Deemed dividend for anti-dilution adjustments to Series B and Series C redeemable convertible preferred stock upon issuance of Series D redeemable convertible preferred stock | $15.0M | |
| Income taxes paid | $1.2M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Maze Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
- Chief executive officerJason Coloma V. Jan 30, 2025 to now6
- PresidentHarold Bernstein Jan 30, 2025 to now7
- Chief financial officerMisbah Tahir Sep 2, 2025 to now8
Board members and other officers (19)
- SVP, FinanceAmy Bachrodt Jan 30, 2025 to now9
- CSBOAtul Dandekar Jan 30, 2025 to now10
- GC and Corp. SecretaryPhillips Courtney Jan 30, 2025 to now11
- Board memberNeil Kumar Mar 31, 2026 to now12
- Board memberPaula Johnson Aug 17, 2026 to now13
- Board memberSophie Kornowski Aug 17, 2026 to now14
- Board memberAlan Colowick Jan 30, 2025 to Jan 30, 202515
- Board memberCatherine A. Sohn Jan 30, 2025 to now16
- Board memberCharles J. Homcy Jan 30, 2025 to now17
- Board memberDaniel K. Spiegelman Jan 30, 2025 to now18
- Board memberJames Brush Jan 30, 2025 to Jan 30, 202519
- Board memberJason Coloma V. Jan 30, 2025 to now6
- Board memberJeffrey K. Tong Jan 30, 2025 to Jan 30, 202520
- Board memberJonathan E. Lim Jan 30, 2025 to now21
- Board memberNancy C. Andrews Jan 30, 2025 to now22
- Board memberNeil Exter Jan 30, 2025 to now23
- Board memberRichard H. Scheller Jan 30, 2025 to now24
- Board memberSekar Kathiresan Jan 30, 2025 to now25
- Board memberHerve Hoppenot Oct 7, 2025 to now26
Timeline
- Jan 30, 2025New chief executive Jason Coloma V. becomes CEO6
Filings
217 filings to the SEC since October 2021: 2 annual reports, 5 quarterly reports, 15 major events, 106 insider forms, 24 large holders, 65 other. The latest 20:
- Oct 2, 20264 EDGAR
- Oct 2, 20264 EDGAR
- Oct 1, 20264 EDGAR
- Oct 1, 2026144 EDGAR
- Oct 1, 2026144 EDGAR
- Sep 8, 20264 EDGAR
- Sep 4, 20264 EDGAR
- Sep 4, 20264 EDGAR
- Sep 4, 2026144 EDGAR
- Sep 4, 20264 EDGAR
- Sep 4, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 2, 2026144 EDGAR
- Sep 2, 2026144 EDGAR
- Sep 2, 2026144 EDGAR
- Sep 2, 2026144 EDGAR
- Sep 1, 2026144 EDGAR
The 217 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 24 such filings since October 2021, the latest 10:
- Aug 14, 2026SCHEDULE 13G/A
- Jul 29, 2026SCHEDULE 13G
- May 15, 2026SCHEDULE 13G/A
- Apr 1, 2026SCHEDULE 13G
- Feb 13, 2026SCHEDULE 13G/A
- Feb 13, 2026SCHEDULE 13G/A
- Feb 6, 2026SCHEDULE 13G/A
- Nov 14, 2025SCHEDULE 13G/A
- Nov 14, 2025SCHEDULE 13G/A
- Nov 13, 2025SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 5,032,915 | $150.2M | 3.3% | +465,641 |
| Trv Gp Iv, LLC | 4,473,958 | $133.5M | 52.6% | No change |
| ARCH Venture Management, LLC | 4,120,053 | $123.0M | 11.2% | No change |
| Deep Track Capital, LP | 3,732,569 | $111.4M | 1.6% | +255,007 |
| BlackRock, Inc. | 3,502,841 | $104.5M | 0.0% | +932,416 |
| Jupiter Topco LLC | 3,408,045 | $101.8M | 0.0% | New |
| Logos Global Management LP | 1,935,000 | $57.7M | 2.5% | +700,000 |
| Vanguard Capital Management LLC | 1,778,222 | $53.1M | 0.0% | +342,566 |
| a16z Capital Management, L.L.C. | 1,702,225 | $50.8M | 0.4% | No change |
| Venrock Adviser, LLC | 1,602,034 | $47.8M | 1.4% | No change |
| Alphabet Inc. | 1,388,583 | $41.4M | 0.0% | No change |
| Braidwell LP | 1,140,040 | $34.0M | 1.3% | New |
| Farallon Capital Management, L.l.c. | 1,107,814 | $33.1M | 0.2% | +734,814 |
| Fmr LLC | 1,056,959 | $31.5M | 0.0% | +192,745 |
| General Catalyst Group Management, LLC | 1,035,910 | $30.9M | 16.4% | No change |
| State Street Corp | 997,533 | $29.8M | 0.0% | +360,811 |
| Driehaus Capital Management LLC | 954,886 | $28.5M | 0.2% | +318,724 |
| Trv Gp V, LLC | 950,800 | $28.4M | 5.7% | No change |
| Jpmorgan Chase & Co | 964,011 | $28.0M | 0.0% | +905,565 |
| Marshall Wace, Llp | 914,572 | $27.3M | 0.0% | +603,933 |
| Geode Capital Management, LLC | 858,054 | $25.6M | 0.0% | +258,087 |
| Citadel Advisors LLC | 852,676 | $25.4M | 0.0% | +76,962 |
| Casdin Capital, LLC | 843,857 | $25.2M | 1.3% | +85,000 |
| ArrowMark Colorado Holdings LLC | 767,383 | $22.9M | 1.0% | No change |
| Woodline Partners LP | 736,216 | $22.0M | 0.1% | +85,987 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7SEC EDGARHarold Bernstein, President
- 8
- 9SEC EDGARAmy Bachrodt, SVP, Finance
- 10SEC EDGARAtul Dandekar, CSBO
- 11
- 12SEC EDGARNeil Kumar, Board member
- 13SEC EDGARPaula Johnson, Board member
- 14SEC EDGARSophie Kornowski, Board member
- 15SEC EDGARAlan Colowick, Board member
- 16SEC EDGARCatherine A. Sohn, Board member
- 17SEC EDGARCharles J. Homcy, Board member
- 18SEC EDGARDaniel K. Spiegelman, Board member
- 19SEC EDGARJames Brush, Board member
- 20SEC EDGARJeffrey K. Tong, Board member
- 21SEC EDGARJonathan E. Lim, Board member
- 22SEC EDGARNancy C. Andrews, Board member
- 23SEC EDGARNeil Exter, Board member
- 24SEC EDGARRichard H. Scheller, Board member
- 25SEC EDGARSekar Kathiresan, Board member
- 26SEC EDGARHerve Hoppenot, Board member